イチョウ葉エキス

One review Ginkgo biloba P.E. A double-blind controlled placebo study of the benefits of women with premenstrual unpleasant symptoms, including 143 women aged 18-45 years, and tracking their two menstrual cycles. On the 16th day of the first cycle, each woman received Ginkgo biloba PE (twice twice a day, 80 mg each time) or placebo, and treatment continued until the 5th day of the next cycle, and on the 16th day of the cycle Restart. The results are impressive. Compared with placebo, ginkgo significantly reduced the main symptoms of premenstrual unpleasant symptoms, especially breast pain and emotional instability.

Although there is currently no double-blind trial of this function, case reports and open studies suggest that ginkgo can cause poor sexual function due to cloczac drugs and other antidepressants.

Flavonoids in ginkgo may stop or relieve certain retinopathy. There are many possible causes of retinal damage, including diabetes and macular degeneration. Macular degeneration (commonly known as age-related macular degeneration or ARMD) is a progressive degenerative eye disease that is predisposed to the elderly. It is the main cause of blindness in the United States. Studies suggest that ginkgo may help maintain vision in ARMD patients.

Dosage: The mainstream opinion is that 120-160 ml doses per day are suitable for the treatment of terminal microcirculation problems including dizziness, tinnitus and intermittent claudication. For the treatment of dementia, mild depression and increased cognitive ability, higher doses (approximately 240 mg/day) can be used. For best results, daily intake is generally divided into 2-3 doses. The criteria for the use of the extract were confirmed to contain at least 24% of ginkgo flavonoid glycosides and 6% terpene lactone - as this is the level at which the extract shows substantial efficacy in each clinical trial.